Translating novel science into life-saving medicines
Targeting those patients most
likely to benefit
Developing precision medicines for cancer
Skip to content
Board of Directors
Tipifarnib – HRAS
Tipifarnib – PTCL
Tipifarnib – MDS
KO-947 (ERK Inhibitor)
KO-539 (Menin-MLL Inhibitor)
Events & Presentations
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck »
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer»
Kura's pipeline consists of small molecule drug candidates designed to inhibit mutated or abnormally functioning signaling pathways that drive cancer growth.
Kura is conducting clinical trials intended to identify and enroll patients most likely to respond to treatment.